Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2016.03.14
Active substance: canagliflozin, dapagliflozin, empagliflozin
After completion of the European safety review by the CHMP, the pharmaceutical entrepreneurs concerned are circulating information on the recommendation to minimise the risk of diabetic ketoacidosis.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN